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Background: Higher plasma n-3 polyunsaturated fatty acids (PUFA) have been associated with a lower risk of age
related cognitive decline, and to beneficially affect cardiometabolic risk factors. A relation exists between metabolic
disorders such as diabetes type 2 and cognitive decline. Results regarding the potential effects of n-3 PUFA on risk
factors in healthy subjects are divergent, and studies regarding the possible relation between cardiometabolic
parameters and cognitive performance are scarce. The objective was to evaluate the effects of five weeks intake of
long chain n-3 PUFA on cognitive performance in healthy individuals, and to exploit the possible relation between
outcomes in cognitive tests to cardiometabolic risk parameters.
Methods: Fish oil n-3 PUFA (3g daily) were consumed during 5weeks separated by a 5 week washout period in a
cross-over placebo controlled study, including 40 healthy middle aged to elderly subjects. Cognitive performance
was determined by tests measuring working memory (WM) and selective attention.
Results: Supplementation with n-3 PUFA resulted in better performance in the WM-test compared with placebo
(p < 0.05). In contrast to placebo, n-3 PUFA lowered plasma triacylglycerides (P < 0.05) and systolic blood pressure
(p < 0.0001). Systolic blood pressure (p < 0.05), f-glucose (p = 0.05), and s-TNF-α (p = 0.05), were inversely related to
the performance in cognitive tests.
Conclusions: Intake of n-3 PUFA improved cognitive performance in healthy subjects after five weeks compared
with placebo. In addition, inverse relations were obtained between cardiometabolic risk factors and cognitive
performance, indicating a potential of dietary prevention strategies to delay onset of metabolic disorders and
associated cognitive decline.
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Long chain n-3 polyunsaturated fatty acids (n-3 PUFA,
docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA)) are important for optimal brain function and
mental health [1,2]. In prospective cohort- [3] and cross-
sectional studies [4] of middle aged and elderly popula-
tions, higher proportions of n-3 PUFA in plasma were
linked to a lower risk of cognitive decline. A number of
studies further reveal that higher fish consumption pro-
moted less decline and better cognitive functions [5-9].
However, controlled intervention trials of the effect of n-
3 PUFA on cognitive functions in healthy subjects are
scarce, and results from the limited number of studies
available are divergent. A double-blind, placebo-
controlled trial in 302 cognitively healthy subjects (65
years) revealed no effects on cognitive domains of atten-
tion, sensorimotor speed, memory, and executive func-
tion after 26 weeks supplementation with 1800 mg/d or
400 mg/d EPA+DHA [10]. Contrary, a randomized,
double-blind, placebo-controlled trial in 458 healthy
subjects resulted in beneficial effects on a visuospatial
learning and episodic memory test after 24 weeks sup-
plementation with 900 mg daily intake of DHA [11]. In
a smaller study, 33 subjects received a diet supplemen-
ted with n-3 PUFA from fish oil (daily, 1.6g EPA + 0.8g
DHA) for 35 days, whereas 16 subjects instead were sup-
plemented with olive oil (placebo) [12]. Supplementation
with n-3 PUFA was associated with improved attentional
functions and mood. In another randomized double-
blind intervention study, fifty-four healthy young adults
were received either n-3 PUFA supplementation (daily
2.3 g of n-3 PUFA; 1.74 g EPA, 0.25 g DHA) or placebo
(olive oil) for 4 weeks [13]. PUFA supplementation was
associated with performing fewer risk-averse decisions.
Cardiometabolic disorders such as the metabolic syn-
drome, impaired glucose tolerance, and diabetes are
associated with higher risk of cognitive decline, e.g. de-
crease in memory and executive functioning [14-16], in-
formation processing speed, attention [17], and overall
intellectual functioning [18,19]. Long chain n-3 PUFA
intervention studies have shown benefits on several key
metabolic risk factors, e.g. lowers the blood pressure and
triglycerides [20], reduce inflammatory markers [21],
and improve glucose metabolism [22] and insulin sensi-
tivity [23].
The present study undertakes to evaluate the effects of
dietary supplementation with n-3 PUFA on cognitive
performance in healthy individuals; and to relate cogni-
tive outcome to cardiometabolic risk parameters. For
this purpose, healthy middle aged to elderly subjects
(51–72 years) with BMI 20–30 kg/m2 were provided n-3
PUFA supplement from fish oil (3 g/day) or placebo for
five weeks, respectively, in a randomized cross-over de-
sign with a five-week wash-out period. Cognitive tests ofworking memory and selective attention were executed
after the n-3 PUFA- and placebo periods, respectively,
and metabolic risk markers were determined in blood
prior to and after the PUFA- and placebo periods.
Subjects and methods
Ethics statement
This study was conducted in compliance with the guide-
lines laid down in the Declaration of Helsinki (ethical
principles for research involving human subjects). All pro-
cedures involving human subjects were approved by the
Regional Ethical Review Board in Lund, Sweden (protocol
2008/5). Written informed consent was obtained from all
subjects.
Study population
Volunteers, 30 women and 14 men aged 51–72 years
(mean ± SD: 63 ± 5 years) with BMI between 20–30 kg/
m2 (mean ± SD: 25 ± 3) from the south of Sweden, were
recruited to the study through advertisement in local
newspapers. Exclusion criteria were blood glucose > 6.1
mmol/L, BMI > 30 kg/m2 and known metabolic dis-
eases, gastro-intestinal disorders or known cognitive de-
cline. Medication for high blood pressure was allowed,
but had to be kept constant during the study period.
The subjects had to be fluent in the Swedish language.
All but one subject (born in UK, but fluent in the Swed-
ish language) were native Swedish.
Recruitment began October 2008. Trials took place be-
tween January 2009 and June 2009. Out of the forty-four
volunteers enrolled in the study, four dropped out after
the first intervention period (two after the placebo
period and two after omega-3); three due to personal
reasons and one was excluded due to reporting suffering
from a disorder affected wakefulness. Forty subjects
completed both intervention periods, but two subjects
were excluded due to detection of abnormal fasting
blood glucose concentrations (7.0 and 6.7 mmol/L, re-
spectively). In total, results from 38 completers (28
women and 10 men) aged 51–72 years (mean 63.3 ± 5.3)
and with BMI between 20–31 kg/m2 (mean 25.0 ± 2.8)
were evaluated. Twenty out of the 38 subjects started
with n-3 PUFA and 18 with placebo. Twenty-two sub-
jects were senior citizens. One of the participants was an
occasional smoker, but didn’t smoke the day before or
during the test days. The participants were interviewed
regarding eating habits and health status prior to the
onset of the study. In addition, at each visit, i.e. prior to
and after each intervention period, a questionnaire
regarding current diet, physical activity, health status
and use of medicine, were filled in. All participants con-
sumed an ordinary Swedish diet, including meat, and
fish every week. The subjects were told to continue with
their habitual diet throughout the study period. When
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stated that there were no major changes in diet or phys-
ical activity during the whole study period. No physical
examination was included. Based on information from
interviews and forms it was revealed that seven partici-
pants were medicated for hypertonia, and one subject
with cholesterol lowering medication (Simvastatin). One
subject was medicated for depression since several years,
without any symptoms and changes in medicine for at
least twelve month. Three participants suffered from
mild osteoarthritis (one was medicated with glucosa-
mine). Post-intervention evaluation of base-line data
revealed that five subjects had high levels of triacylgly-
cerides (2.3, 2.3, 2.7, 2.8, and 3.3 mmol/L) and three sub-
jects showed borderline concentrations (1.8, 2.0, and 2.2
mmol/L).
No major side effects or problem to consume the sup-
plements were reported.
Test product and placebo
Test product
The dietary supplement consisted of capsules containing
1000 mg fish oil, whereof 600 mg was n-3 PUFA (EPA
300 mg, DHA 210 mg and 90 mg unspecified) (Pikasol
fish oil capsules, Axellus VS, ORKLA, Oslo, Norway).
Five capsules per day were consumed; resulting in a total
daily intake of 3 g n-3 PUFA (EPA 1500 mg, DHA 1050
mg and 450 unspecified).
Placebo
The placebo supplement was provided as two tablets per
day containing in total 366 mg dicalcium phosphate (E
341), 150 mg microcrystalline cellulose (E 460) and 4
mg magnesium salts of fatty acids (E 470b). The placebo
was provided by Axellus VS, ORKLA, Oslo, Norway.
Study design
The study had a cross-over, randomised but balanced
design. Out of the forty-four subjects described above,
forty completed both intervention periods. Twenty sub-
jects (14 women and 6 men) started with five weeks
daily consumption of omega-3 PUFA, and consumed
placebo in a second five weeks intervention period, and
20 subjects (14 women and 6 men) were enrolled to
start with five weeks consumption of the placebo. The
subjects visited the experimental department at four
occasions; in the mornings prior to start of each inter-
vention periods, and in the mornings after finishing the
PUFA- and placebo period, respectively.
Protocol
The evening prior to attendance, at 9.00 pm. the test
subjects ate a standardized meal, consisting of white
wheat bread with optional spread, and had coffee, tea orwater to drink. Thereafter they were fasting until the ar-
rival at the research department. At 07.45 am, the test
subjects were weighed and seated to rest for a minimum
of 10 minutes before the blood pressure was registered
and fasting blood samples collected. A standardized
breakfast was served consisting of white wheat bread
(Dollar Storfranska, Lockarps bakery, Malmö, Sweden)
and apricot marmalade (Ica, Sweden) corresponding to
in total 55 g available carbohydrates. Water, 250 ml, or a
plain cup of decaffeinated coffee or tea was served with
the bread. The breakfast was consumed within 15 min.
Thereafter, cognitive tests were performed and capillary
blood tests were collected repeatedly up to 180 min post
commencing the breakfast. The occupation during in-
between the cognitive tests were standardized such that
the subjects performed Sudoku.
Setting
The study was performed at the division of Applied Nu-
trition and Food Chemistry, Department of Food Tech-
nology, Engineering and Nutrition, Lund University,
Sweden.
Cognitive tests
Prior to the intervention periods, i.e. at visit no. 1 and 3,
the subjects performed pilot versions of the cognitive
tests to reduce learning effects and stress at the cogni-
tive test days. Measurements of cognitive performance
were performed after completion of each intervention
period, i.e. at visit no. 2 and 4.
Working memory (WM) test
The tests employed in the present study represent an ex-
tension of the methodology developed by Radeborg et al.
[24]. There are several reasons for choosing WM as a
measure of cognitive performance in this study. WM
can be defined as a system responsible for simultaneous
temporary short term storing and processing of informa-
tion, and is involved in many everyday activities; such as
mathematical problem solving where one often has to
remember part of the result in a calculation while per-
forming further mathematical operations. WM represent
a fundamental ability for higher-level cognitive pro-
cesses. Thus, measures of WM capacity have been
shown to correlate significantly with activities as diverse
as e.g. reading comprehension [25], note taking [26], the
following of directions [27], reasoning [28], and complex
learning [29]. Some authors [30,31], even claim that
WM and general problem solving ability or intelligence,
as measured by e.g. Raven´s Matrices, reflect nearly
identical constructs. However, whereas intelligence tests
generally only can be administered once due to risk of
considerable learning effects, WM can be measured re-
peatedly. In total, three oral WM-tests were included at
Nilsson et al. Nutrition Journal 2012, 11:99 Page 4 of 9
http://www.nutritionj.com/content/11/1/99each experimental day (performed at 60, 110, and 160
min). Two of the tests (at 60 and 160 min) were exe-
cuted principally as described previously [32], modified
by including 12 sets of 3–5 short declarative sentences
(four of each number) instead of 4 sentences in all sets.
As previously, the sentences could be either semantically
meaningful of the type ‘the boy brushed his teeth’, or
nonsensical, such as ‘the rabbit struck the idea’. The test
leader was blind to the product provided to the test sub-
jects. The sentences were read one by one to the sub-
jects. Immediately after a sentence, he/she had to
indicate if it was a semantically meaningful sentence or
not. After each set of sentences the subjects had to re-
peat, in any order, the first noun in each of the sen-
tences. One test could at maximum generate 48 credits.
The tests consisted of equal number of sentences that
were semantically meaningful (24 credits) and nonsens-
ical (24 credits). It has been described that remembering
of a noun in a semantically nonsensical sentence is more
demanding [24]. The WM-test could therefore be
divided into two parts differing in degree of difficulty.
The third WM-test was performed at 110 min and was
similar to the tests just described, with the exception of
that instead of short sentences, the test was composed
of simple additions of two single digit numbers. The test
leader presented orally the two figures to be added, and
the test subjects were supposed to immediately give an
oral answer to the addition. After a set of 3–5 additions,
the subjects had to repeat the first figure in each
addition. The test could at maximum generate 48 cred-
its. One WM-test took approximately 8–10 min to per-
form. Four different but comparable WM-tests
composed of sentences and two different but compar-
able WM-tests composed of figures were included in the
study.
Selective attention (SA) test
The test was based on spatial perception and primarily
measured the ability to sustain a prolonged attention,
and to control and split the attention to the entire pic-
ture on a computer screen. Like the WM-test, the test
also dealt with simultaneous temporary storing and pro-
cessing of information (WM capacity). The storing time
required was however shorter compared with the WM-
test, whereas the time pressure was higher. The SA was
measured using a computerized test made up of 96 pic-
tures, each shown for two seconds on the computer
screen. The pictures consisted of a square on a white
background, divided into four equally sized smaller
squares. One of the smaller squares was red, one square
was green, and two squares were uncolored (white),
resulting in a total of 12 unique picture combinations.
The subjects had to remember the positions of the col-
ored squares, and to compare each new picture thatemerged on the screen with the preceding one. Each
time a new picture emerged, either the green, the red, or
none of the colored squares were in the same position
compared with the previous picture. Within the two sec-
onds each picture was shown, the subjects were sup-
posed to indicate by pressing one of three different keys
on the keyboard, which of the three possible alternatives
that occurred for each new picture. The test began with
a short training session, and took approximately 10 min
to perform. The test was scored with the number of cor-
rect responses (CR, total 95 credits) and for the reaction
time (RT) needed to give the answer (i.e. press one of
the keys).
Metabolic risk markers
Physiological test variables were determined prior to and
after completing each intervention period. Blood pres-
sure was determined with an automatic blood pressure
cuff (Digital Automatic Blood Pressure Monitor, Model
M3 Intelligence, OMRON HEALTHCARE CO., LTD,
Kyoto, Japan). Finger-prick capillary blood was with-
drawn at fasting and at 15, 30, 45, 60, 90, 125, 160 and
180 min after the start of the standardized breakfast for
determination of glucose concentrations and glucose tol-
erance (HemoCueWB-glucose, HemoCue AB, Ängel-
holm, Sweden). Venous blood was withdrawn for
determination of fasting levels of serum (s) insulin, s-
TNF-α, s-adiponectin, s-free fatty acids (s-FFA), s-tria-
cylglycerol, and plasma (p) malonedialdehyd (MDA).
The venous blood samples were centrifuged and plasma
and serum separated and stored in a freezer (−40°C)
until analyzed.
Methods for analyses of insulin, FFA, adiponectin and
triacylglycerols are described elsewhere [33]. S-TNF-α
was determined with a sandwich enzyme immunoassay
kit (TNF-α ELISA Kit, Immunodiagnostik AG, Germany).
Plasma MDA was determined by measure of lipid per-
oxidation as TBARS as is described in [34], modified by
excluding the n-butanol.
Calculations and statistical methods
Primary outcome measure was results in the WM-test.
The sample size was calculated based on a study in
healthy middle aged subject, including a similar WM-
test as was used in the current study [24]. A significant
effect (p < 0.05) was detected on WM, with an effect size
(Cohen´s d) of d = 0.75. In the present study we
assumed a smaller effect (d = 0.50), resulting in a power
of 0.86 in a one tailed statistical hypothesis test, and a
power of 0.77 in a two tailed test. In a power calculation,
based on table 9–9 and 9–10 in Aron and Aron 82003:
Statistics for Psychology, 33 subjects would be enough
to get a 80% power. However, to have the possibillity to
have a balanced design (balansed with respect to order
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involve 40 subjects.
The results are expressed as means ± SEM. The influ-
ences of the test- and placebo products on the cognitive
tests were analyzed by repeated measures ANOVA at
the test points, with order of test meals and test meals
as independent variables and performance on cognitive
tests as dependent variables. Statistical calculations were
performed in Stat View 5.0 and SuperAnova 1.11. Treat-
ment effects on physiological test parameters (based on
changes from baseline in the intervention -and placebo
periods, respectively) were assessed with analysis of vari-
ance (ANOVA general linear model) in MINITAB Statis-
tical Software (release 13.32; Minitab inc., State College.
PA. USA). Time effects on cognitive tests were assessed
with analysis of variance (ANOVA general linear model)
followed by Tukey’s pairwise multiple comparison
method for means (adjusted means were reported) in
MINITAB. Participants acted as their own control.
GraphPad Prism (version 4.03; GraphPad Software, San
Diego, CA, USA) was applied for calculation of blood
glucose incremental areas under the curves (IAUC).
Blood glucose IAUC (0–90 min) was used as an estimate
of glucose tolerance. Pearson correlations were applied
to study relations between physiological test parameters
and results in the cognitive tests. Values of P ≤ 0.05 were
considered statistically significant. Cohen’s d is presented




The outcomes from the WM-tests are presented in
Table 1. Five weeks dietary supplement with n-3 PUFA
from fish oil improved performance in the WM-test at
60 min compared with the placebo F(1,36) = 4.41, p =
0.04, d = 0.26. There was a tendency towards improve-
ment after n-3 PUFA in total performances in the WM-
tests based on sentences (WM-tests at 60 + 160 min) FTable 1 Results in the WM-tests following five weeks
daily dietary supplementation with 3 g omega-3 PUFA
from fish oil or placebo, respectively1
Treatments
WM-tests 2(max 48 credits) Omega-3 Placebo
60 min 31.4±0.8a 30.0±1.0b
110 min 33.8±1.4a 33.3±1.4a
160 min 30.4±0.9a 29.6±1.0a
1Data are given as means per treatment ± SEM, n = 38, but only 37 subjects
performed the WM-test at 110 min (19 subjects started with placebo and 18
subjects started with PUFA) due to one subjects did not perform the test in
time. Labeled means in a row without a common letter differ, p < 0.05
(ANOVA).
2 At 60 min and 160 min the subjects were supposed to recall nouns and at
110 min the subjects were supposed to recall figures.(1,36) = 3.43, p = 0.07, d = 0.20. When including only
the most demanding part in the statistical calculations, i.
e. the semantically nonsensical sentences, the differences
in performance after n-3 PUFA compared with placebo
became more substantial: WM-tests at 60 min: F(1,36) =
6.87, p = 0.013, d = 0.34, and WM-tests at 60 + 160
min: F(1,36) = 6.87, p = 0.015, d = 0.31, Table 2.
There were no differences in the performance of the
WM-tests depending on the consumption sequence of
the test product (total word retrieval: P=0.85, figure re-
trieval P=0.45). However, there was a [treatment*con-
sumption sequence] interaction in the WM-tests, total
word retrieval F(1,36 )= 5.86, p = 0.021 and figure re-
trieval F(1,35) = 6.50, p = 0.015, that revealed better per-
formance after n-3 PUFA compared with the placebo in
the subject group (20 subjects) that had PUFA in the
first intervention period (total word retrieval: F(1,19) =
9.05, p = 0.007, d = 0.37, figure retrieval: F(1,19) = 4.47,
p = 0.048, d = 0.25), whereas there were no significant
differences depending on treatment in the 18 subjects
that started with placebo (word retrieval: p = 0.69, figure
retrieval: p= 0.29). There were no significant time effects
in performance between the WM-tests performed at 60
min and 160 min (p = 0.15). The absence of improve-
ment with time indicates that there were no learning
effects in the WM-tests.
SA-tests
The results from the SA-tests (CR) are displayed in
Table 3. Even if not significant, there was a tendency to-
wards better performance after n-3 PUFA supplementa-
tion compared with the placebo in the total SA-test (SA-
test 1–4, F(1,34) = 3.10, p = 0.087, d = 0.10). No differ-
ences in the performance were found in the SA-tests de-
pending on the consumption sequence (p = 0.15) but
there were [treatment*consumption sequence] interac-
tions (total SA-test), F(1,34) = 34.08, p= 0.0001, with
better performance after the placebo F(1,18) = 9.28, p =
0.007, d = 0.34 or PUFA F(1,17) = 7.40, p = 0.015, d =
0.29, depending on being consumed in the secondTable 2 Results in the most demanding part of the WM-
tests following five weeks daily dietary supplementation
with 3 g omega-3 PUFA from fish oil or placebo,
respectively1
Treatments
WM-test(max 24 credits) Omega-3 Placebo
60 min2 14.8±0.6a 13.7±0.5b
160 min 14.5±0.5a 13.8±0.5a
Total (60+160 min)3 29.3±0.9a 27.5±1.0b
1The data shows results for the most demanding part of the tests, i.e. recall of
a noun in semantically nonsensical sentences. Data are given as means per
treatment ± SEM, n = 38. Labeled means in a row without a common letter
differ, 2p = 0.01, 3p = 0.015 (ANOVA).
Table 3 Results in the SA-tests following five weeks daily
dietary supplementation with 3 g omega-3 from fish oil
or a placebo product, respectively1
Treatments
SA-test(max 95 credits) Omega-3 Placebo
Fasting 77.39±2.57 75.28±2.79
45 min 80.84±1.92 79.97±2.29
95 min 81.16±2.02 81.43±1.90
145 min 81.73±1.77 81.62±2.08
Total (0-145min)2 322.5±7.80 318.3±8.78
1Data are given as means per treatment ± SEM, n = 36 at fasting (18 subject
started with PUFA and 18 with placebo), n = 37 at the rest of the time points
(19 subject started with PUFA and 18 with placebo) due to 2 and 1 subjects,
respectively, performed the test incorrectly.
2 The total SA-test (test 1–4), p = 0.087 (ANOVA). The statistical calculations for
the total SA-test is based on n = 36, the number of subjects that performed all
four tests.
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from the first to the second test occasion indicate learn-
ing effects in the SA-test. In addition, there was also a
time effect during the test day, meaning that the subjects
performed inferior in the first SA-test (fasting) comparedTable 4 Results of the physiological test parameters before a
PUFA from fish oil and placebo, respectively
Physiological parameters Omega-3
Before After Δ-O
Weigh (kg) 72.1±2.0 72.3±2.0
Systolic BP (mmhg)4 134±3 127±3 −
Diastolic BP (mmhg)5 79.2±1.4 76.9±1.4 −2
f-Glucose (mmol/L, n=37) 5.4±0.1 5.5±0.1
ΔGlucose peak (mmol/L) 4.2±0.2 4.0±0.2 −
Glucose 90 min IAUC (mmol*min/L) 217±13 213±11
Insulin (pmol/L)6 35±3 40±3
FFA (mmol/L)7 0.28±0.02 0.26±0.02 −0
Triglycerides (mmol/L)8 1.63±0.10 1.45±0.09 −0
TNF-α (ng/L) 9.8±1.0 9.3±0.9 −0
Adiponectin (mg/L) 12±1 12±1
Malondialdehyd (μmol/L) 2.0±0.1 2.0±0.1
1 Changes (Δ) in test variables after 5 weeks PUFA supplementation compared with
placebo supplementation compared with baseline (prior to start of placebo).
*: p < 0.05, ***: p < 0.001 (ANOVA) with respect to differences from baseline after 5
†: p < 0.05 (ANOVA) with respect to differences from baseline after 5 weeks intake o
3 P-values for differences between effects of PUFA (Δ-PUFA) and effects of placebo
4 The systolic blood pressure was significantly more suppressed after 5 weeks supp
(1,36) = 4.56, p = 0.04, d = 0.46]. The systolic BP was significantly lower after, comp
n=37 in the BP analysis due to one participant failed to rest prior to one measurem
5 The diastolic BP was significantly lower after, compared to prior to the omega-3 p
diastolic BP after, compared with prior to the placebo period [F(1,36) = 3.31, p = 0.0
6 The s-insulin concentrations were significantly higher after, compared to prior to t
(1,37) = 4.11, p = 0.050, d = 0.30], respectively.
7 There was a tendency towards concentrations of FFA to be more suppressed com
concentrations of FFA after 5 weeks supplementation with omega-3 PUFA did not d
8The concentrations of s-triglycerides were significantly lower after, compared to pr
more suppressed after 5 weeks supplementation with omega-3 PUFA compared wi
Abbreviations: ns: no significant differences between Δ-PUFA and Δ- placebo (ANO
blood pressure.
Values are mean±SEM. Statistical evaluations are performed with analysis of variancwith the other three SA-tests F(3,107) = 16.35, p =
0.000. No differences were seen in reaction times de-
pending on n-3 PUFA or placebo (results not shown).
Relations between cognitive performance and metabolic
risk markers
The systolic blood pressure (F(1,36) = 4.56, p = 0.04, d =
0.46) and s-triglycerides (F(1,37) = 4.05, p = 0.05, d =
0.59) were significantly more suppressed after 5 weeks
supplementation with omega-3 PUFA, compared with
after the placebo (based on differences between after
completion and prior to start of each intervention
period). The results of the effects of n-3 PUFA on meta-
bolic test markers are compiled in Table 4. As a general
feature, the systolic blood pressure was inversely related
to the performance in the cognitive tests. This relation
was most pronounced in the WM-tests after the inter-
vention with n-3 PUFA (WM 60 min: r = −0.35, p =
0.034, WM 110 min: r = −0.38, p = 0.022, WM 160 min
(in the most difficult part): r = −0.36, p = 0.029). The
fasting glucose concentrations were inversely related to
the performance in the WM test at 110 min after n-3nd after five weeks interventions with 3g/d omega-3
Placebo
mega-31 Before After Δ- Placebo2 Δ3
0.2±0.1 72.3±2.0 72.2±2.0 −0.1±0.1 ns
7±2*** 132±3 131±3 −1±2 P≤0.05
.24±1.0* 78.8±1.2 77.3±1.4 −1.46±0.8 ns
0.1±0.1 5.5±0.1 5.4±0.1 −0.1±0.1 ns
0.2±0.2 4.3±0.2 4.2±0.2 −0.1±0.2 ns
−4±1 225±10 226±11 1±10 ns
5±2* 37±3 43±04 6±3† ns
.03±0.02 0.28±0.02 0.31±0.02 0.03±0.02 P=0.055
.19±0.07* 1.58±0.10 1.66±0.11 0.08±0.07 P≤0.05
.48±0.44 8.9±0.8 8.5±0.8 −0.43±0.30 ns
0±0 12±1 12±1 0±0 ns
0.1±0.1 1.9±0.1 2.0±0.1 0.1±0.1 ns
baseline (prior to start of PUFA). 2 Changes (Δ) in test variables after 5 weeks
weeks intervention with PUFA.
f the placebo.
(Δ- placebo).
lementation with omega-3 PUFA compared with after 5 weeks with placebo [F
ared to prior to the omega-3 period [F(1,36) = 14.70, p = 0.0005, d = 0.33].
ent.
eriod [F(1,36) = 5.27, p = 0.028, d = 0.26]. There was a tendency toward lower
8, d = 0.19].
he omega-3 period [F(1,37) = 6,14, p = 0.018, d = 0.28] and placebo period [F
pared with after the placebo [F(1,37) = 3.94, p = 0.055, d = ], however, the
iffer compared to prior omega-3 PUFA.
ior to the omega-3 period [F(1,37) = 6.87, p = 0.013, d = 0.32], and significantly
th after the placebo [F(1,37) = 4.05, p = 0.05, d = 0.59 ].
VA), f: fasting. P: plasma. S: serum. IAUC: incremental area under the curve. BP:
e (ANOVA general linear model). N = 38, except for evaluation of BP, (n = 37).
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wards an inverse relation between f-glucose concentra-
tions after the placebo period and WM test at 60 min
(the most difficult part, r = −0.23, p = 0.069). Concentra-
tions of triacylglycerides tended to be inversely related
to cognitive performance. The strongest relation was
seen in the WM-test at 60 min after start of the standar-
dized breakfast following n-3 PUFA (r = −0.30, p =
0.066). Serum TNF-α concentrations were inversely
related to the performance in the SA-test at fasting, after
the placebo period (r = −0.33, p = 0.05).
Evaluations of relations between improvements in cog-
nitive performance (WM-1) and lowering of triacylgly-
cerides, or systolic blood pressure, were performed in
subject groups showing lower triacylglyceride concentra-
tions (n=23) or systolic blood pressure (n = 25) after n-3
PUFA compared with after placebo. Pearson correlations
revealed a tendency towards a relation between
improved performance (WM-1) and lowered systolic
blood pressure(r = −0.37, p = 0.072), whereas no rela-
tions were detected between effects on triacylglycerides
and improvement in WM-1.
Discussion
The results show that daily intake of n-3 PUFA from fish
oil during five weeks significantly improved cognitive
functions (WM capacity) in healthy subjects. In addition
there was a tendency towards better performance in the
SA test after the n-3 PUFA period (SA-test no. 1–4, p =
0.087). DHA + EPA are involved in a number of brain
functions that may modulate cognitive functions, e.g.
neurotransmission and regulation of signal transduction
pathways [1], and are also important structural compo-
nents in neuronal cell membranes. In addition n-3 PUFA
possesses several anti-inflammatory properties [36]. A
growing body of data link chronic inflammation to poorer
cognitive functions [37]. For example, in a middle-aged
group of healthy subjects, circulating levels of IL-6 were
inversely related to performance on a cluster of cognitive
tests evaluating auditory recognition memory, attention,
working memory, and executive function [37]. Interest-
ingly, there was an inverse relation between TNF-α con-
centrations and performance in the SA-test in the present
study. The relationship between inflammation and cogni-
tive performance indicate that n-3 PUFA may be beneficial
to cognitive functions due to a general anti-inflammatory
effect; involving also effects on neuro-inflammation. Low
grade chronic inflammation is increasingly also recognised
as an important factor in the development of metabolic
disorders such as diabetes type 2 [38] and cardiovascular
disease [39] ( i.e. conditions that predispose for cognitive
decline [14,40-42]).
In addition to improved cognitive performance, n-3
PUFA improved acknowledged cardiometabolic riskmarkers, i.e. systolic blood pressure and triglycerides.
The systolic blood pressure was inversely related to per-
formance on cognitive tests and there was also a ten-
dency toward an inverse relation between cognitive
performance and triglycerides (P = 0.066). The reduc-
tions in triglycerides and systolic blood pressure in the
present cohort of healthy mature subjects were similar
to those previously described in hyper-triglyceridaemic
subjects after daily intake of 1g of fish- or seal oil for six
weeks [20], highlighting the cardioprotective properties
of n-3 PUF in healthy subjects.
The novelty of the present investigation is that it sim-
ultaneously evaluated effects of n-3 PUFA on cognition,
as well as on cardiometabolic risk markers in healthy
subjects. The relation between higher levels of cardiome-
tabolic risk markers and inferior cognitive performance
in healthy subjects, as observed in the present study,
highlights the potential of a preventive dietary approach
in the combat of both metabolic disorders and asso-
ciated cognitive decline.
Available studies of effects of n-3 PUFA have mainly
used different fatty acids as placebo. In the current study
we included a non-oil based placebo product. The ra-
tionale for not choosing oil for placebo is that several
fatty acids possess known or suggested metabolic and/or
cognitive effects, and are therefore not inert to the test
variables investigated in studies of metabolism and cog-
nition [8,43-45]. A potential limitation of our study
relates to the fact that the n-3 PUFA was administered
in the form of a capsule, whereas the placebo treatment
was in tablet form, since it was impossible to seal a cap-
sule containing water. However, the test subjects were
uninformed as to the activity of the PUFA and placebo
supplement. It should also be noted that it is difficult to
blind an intake of fish oil due to side effects such as
‘fishy burps’ [46]. An additional potential study limita-
tion may be that no data is available concerning subjects’
blood- and/or red blood cell membrane phospholipid
concentrations of n-3 PUFA.
Conclusions
In conclusion, the present study reveals that five weeks
daily intake of omega-3 PUFA from fish oil has the poten-
tial to improve cognitive functions and cardiometabolic
risk factors in a healthy middle aged to elderly cohort. The
relationship between outcome in cognitive tests and cardi-
ometabolic risk factors highlights the importance of early
dietary prevention to prevent cognitive decline secondary
to cardiometabolic disorders. The dietary prevention strat-
egy should preferably include fish in quantities to supply
sufficient amounts of PUFA, in addition to other food
groups with potential metabolic benefits e.g. whole grain,
low-glycaemic index foods, fruits, berries, vegetables, and
prebiotics [33,47-50]. Further studies are needed to clarify
Nilsson et al. Nutrition Journal 2012, 11:99 Page 8 of 9
http://www.nutritionj.com/content/11/1/99the underlying mechanism of the enhanced cognitive ef-
fect of omega-3 PUFA, and the relationship to cardiome-
tabolic risk markers.
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